Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

被引：0
|
作者：
de Jesus, Cabrera-Lopez Teresita [1 ]
Edgar, Perez-Barragan [2 ]
Ruben, Nava-Campos Carlos [1 ]
Marla, Toiber-Rodriguez [3 ]
Carlos, Rodriguez-Aldama Juan [2 ]
Adrian, Cruz-Flores Raul [4 ]
Andrea, Gonzalez-Rodriguez [5 ]
机构：
[1] Clin Especializada Condesa Iztapalapa, Dept Gynecol & Care Victims Sexual Assault, Mexico City, Mexico
[2] Clin Especializada Condesa Iztapalapa, Dept Infect Dis, Combate Celaya 352, Mexico City 09730, Mexico
[3] Clin Especializada Condesa Iztapalapa, Dept Mental Hlth, Mexico City, Mexico
[4] Clin Especializada Condesa Iztapalapa, Dept Epidemiol, Mexico City, Mexico
[5] Clin Especializada Condesa, Mexico City, Mexico
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词：
bictegravir/emtricitabine/tenofovir alafenamide; HIV; INSTI; post-exposure prophylaxis; sexual assault; HIV; HEALTH; RECOMMENDATIONS; EXPOSURE;
D O I：
10.1093/ofid/ofae436
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-world persistence with dolutegravir/lamivudine versus bictegravir/ emtricitabina/tenofovir-alafenamide among people with HIV
    Martin-Zaragoza, Lorena
    Sanchez-Rubio-Ferrandez, Javier
    Onteniente-Gonzalez, Alberto
    Gomez-Bermejo, Marcos
    Rodriguez-Alvarez, Sergio Julio
    Monereo-Alonso, Alfonso
    Molina-Garcia, Teresa
    FARMACIA HOSPITALARIA, 2024, 48 (04) : 171 - 175
  • [32] An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1
    Liu An
    Xin Ruolei
    Zhang Hongwei
    Dai Lili
    Wu Ruojun (Esther)
    Wang Xi
    Li Aixin
    Hua Wei
    Li Jianwei
    Shao Ying
    Gao Yue
    Wang Zhangli
    Ye Jiangzhu
    A bu dou re xi ti Gulimila
    Li Zaicun
    Sun Lijun
    中华医学杂志英文版, 2022, 135 (22)
  • [33] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Inès Devred
    Kick Kayembe
    Nadia Valin
    Hayette Rougier
    Bruce Wuembulua Shinga
    Sidonie Lambert-Niclot
    Thibault Chiarabini
    Marie-Caroline Meyohas
    Karine Lacombe
    BMC Infectious Diseases, 23
  • [34] Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
    Devred, Ines
    Kayembe, Kick
    Valin, Nadia
    Rougier, Hayette
    Shinga, Bruce Wuembulua
    Lambert-Niclot, Sidonie
    Chiarabini, Thibault
    Meyohas, Marie-Caroline
    Lacombe, Karine
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [35] A phase IV open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to HIV-1
    Liu, A.
    Xin, R.
    Zhang, H.
    Dai, L.
    Wu, R. E.
    Wang, X.
    Li, A.
    Li, J.
    Shao, Y.
    Gao, Y.
    Wang, Z.
    Ye, J.
    Abudourexiti, G.
    Li, Z.
    Sun, L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 219 - 220
  • [36] Tenofovir alafenamide prophylaxis post-liver transplantation: a real-world study in patients with chronic kidney disease
    Sinakos, E.
    Panas, P.
    Fragkou, N.
    Antoniadis, N.
    Katsanos, G.
    Tsakni, E.
    Oikonomou, T.
    Notopoulos, A.
    Tsoulfas, G.
    Goulis, I
    Akriviadis, E.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2022, 85 (02) : 331 - 337
  • [37] Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
    Su, Pei-Yuan
    Su, Wei-Wen
    Hsu, Yu-Chun
    Huang, Siou-Ping
    Yen, Hsu-Heng
    PEERJ, 2021, 9
  • [38] Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study
    Peng, Wen-Ting
    Jiang, Chuan
    Yang, Fei-Lan
    Zhou, Nian-Qi
    Chen, Ke-Yu
    Liu, Jin-Qing
    Peng, Shi-Fang
    Fu, Lei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (44) : 5907 - 5918
  • [39] Effectiveness of Bictegravir/ Emtricitabine/Tenofovir Alafenamide(BIC/FTC/ TAF) as switch strategy in virologically suppressed: Real world data from monocentric cohort
    Passerotto, R. A.
    Lamanna, F.
    Farinacci, D.
    Dusina, A.
    D'Angelillo, A.
    Ciccullo, A.
    Baldin, G.
    Mozzetta, I.
    Visconti, E.
    Di Giambenedetto, S.
    Borghetti, A.
    HIV MEDICINE, 2023, 24 : 139 - 140
  • [40] Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Yang, Xiaoyan
    Ma, Shujing
    Kong, Linghong
    Song, Chunli
    Song, Yebing
    Ren, Tingting
    Long, Hai
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
12345